INTERSECT ENT, INC. XENT Income Statement

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12
Revenue
109,142	108,472	96,301	78,708	61,593	38,587	17,931	5,863
Cost of sales
21,773	22,613	15,499	13,003	12,288	10,223	8,150	3,837
Gross profit
87,369	85,859	80,802	65,705	49,305	28,364	9,781	2,026
Operating expenses:
Selling, general and administrative
108,480	91,603	80,045	72,926	59,637	36,111	18,229	9,251
Research and development
24,283	19,262	18,360	18,890	16,608	10,331	9,518	9,260
Total operating expenses
132,763	110,865	98,405	91,816	76,245	46,442	27,747	18,511
Loss from operations
-45,394	-25,006	-17,603	-26,111	-26,940	-18,078	-17,966	-16,485
Interest income and other, net
2,400	2,084	1,240	889	306	-284	-403	156
Interest and other expense
-	-	-	-	-	-	-	36
Net loss
-42,994	-22,922	-16,363	-25,222	-26,634	-18,362	-18,369	-16,365
Other comprehensive income (loss):
Unrealized (loss) gain on short-term investments, net
94	51	-55	-45	8	-	-	7
Comprehensive loss
-42,900	-22,871	-16,418	-25,267	-26,626	-18,362	-18,369	-16,358
Net loss per share, basic and diluted
-1.37	-0.76	-0.56	-0.89	-1.02	-1.61	-12.57	-16.38
Weighted average common shares used to compute net loss per share, basic and diluted
31,388	30,313	29,119	28,420	26,159	11,384	1,461	999